Drug Profile
Pirenzepine topical - WinSanTor
Alternative Names: Topical pirenzepine - WinSanTor; WST 057; WST-1; WST01; WST1/analgesic; WST57Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator University of California, San Diego; University of Manitoba
- Developer WinSanTor
- Class Antidementias; Antiulcers; Benzodiazepinones; Gastric antisecretories; Piperazines; Pyridones; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors; Muscarinic M1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic neuropathies; Peripheral nervous system diseases; Type 2 diabetes mellitus
- No development reported Neuropathic pain
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Neuropathic-pain in USA (Topical)
- 27 Jun 2023 Pirenzepine topical - WinSanTor receives Fast Track designation for Diabetic neuropathies [Topical] in USA
- 27 Jun 2023 WinSanTor plans to meet US FDA for post phase II in Diabetic peripheral neuropathy (WinSanTor pipeline, June 2023)